Development and external validation of interpretable machine learning models for 7-, 14-, and 28-day mortality in sepsis-associated liver injury
Related Experiment Videos
Hao Yao1,2, Zhaopu Li2, Jinxiao Lü2
1Critical Care Medicine Department, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China.
Background:
Mortality in sepsis-associated liver injury (SALI) remains high, and early risk stratification is difficult. Existing prognostic models commonly focus on a single endpoint, usually 28-day mortality, and rarely undergo independent external validation.
Methods:
We developed machine-learning models using clinical features recorded during the first 24 h to predict all-cause in-hospital mortality within 7, 14, and 28 days. In MIMIC-IV (v3.1), 1,550 adults meeting the prespecified SALI criteria were allocated to a training cohort (n = 1,119) and a held-out internal validation cohort (n = 431). An independent Chinese cohort from Xiaogan Central Hospital (n = 229; 28-day in-hospital mortality, 45.9%) was used for external validation. One hundred candidate pipelines were evaluated using stratified 10-fold cross-validation. SHAP was used to describe feature attribution across prediction horizons.
Results:
AUROCs in the held-out internal validation cohort were 0.840, 0.841, and 0.850 for 7-, 14-, and 28-day mortality, respectively; corresponding external AUROCs were 0.720, 0.717, and 0.763. The external 28-day model outperformed modified SOFA (0.763 vs. 0.673; P = 0.011) and MELD-Na (0.763 vs. 0.636; P = 0.002). A parsimonious logistic-regression sensitivity model achieved an external 28-day AUROC of 0.762, not significantly different from the full model (P = 0.970). The 14-day model was miscalibrated externally; recalibration improved the calibration slope from 0.563 to 0.970 but did not materially improve the Brier score. SHAP rankings varied across horizons and were interpreted descriptively rather than causally.
Conclusion:
The models showed moderate transportability to one independent retrospective cohort. Multicentre prospective validation is needed before clinical implementation.